Can the generic antiretroviral industry support access to a universal antiretroviral regimen?
Curr Opin HIV AIDS
; 12(4): 390-397, 2017 Jul.
Article
de En
| MEDLINE
| ID: mdl-28441147
ABSTRACT
PURPOSE OF REVIEW The generic antiretroviral (ARV) industry played a critical role in the massive scale-up of HIV treatment in low-income and middle-income countries since 2000. As the global community looks ahead to a universal antiretroviral regimen, this article considers the industry's role in supporting universal access to affordable, simpler, more durable, and tolerable HIV treatment regimens. RECENT FINDINGS:
Generic manufacturers made treatment scale-up in low-income and middle-income countries possible through reducing prices, combining molecules from different originator companies to develop optimal fixed-dose combinations, and investing in production capacity to meet escalating demand. Achieving scale-up of a universal regimen will require continued partnership in these areas. Collaboration on the demand and supply sides of the ARV marketplace will be required to foster a healthy and sustainable marketplace for new regimens. This includes clear priority setting from the global treatment community on priority products; predictable demand; regulatory prioritization of optimal products; effective tendering and procurement practices that enable multiple suppliers to participate in the market; coordinated product introduction efforts between Ministries of Health, partners, and civil society; and transparency from both buyers and suppliers to promote and monitor supply security.SUMMARY:
New regimens will benefit people living with HIV, as well as buyers and generic suppliers, by maximizing existing production capacity and treatment budgets to reach the 90-90-90 goals.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Infections à VIH
/
Médicaments génériques
/
Coûts des médicaments
/
Antirétroviraux
Type d'étude:
Prognostic_studies
Limites:
Humans
Langue:
En
Journal:
Curr Opin HIV AIDS
Sujet du journal:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Année:
2017
Type de document:
Article
Pays d'affiliation:
Inde